The treatment for the intractable and advanced targeffing the angiogenesis and immuno-reaction

针对血管生成和免疫反应的疑难晚期疾病的治疗

• 批准号: 14571196
• 负责人: NAGANO Hiroaki
• 金额: $ 2.24万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571196/
• 关键词: hepatocellular carcinoma; IFN-α; angiogenesis; TRAIL; TRAIL receptor; Fas; FasL; NK cell; IFN併用化学療法; Fas-L; 門脈内腫瘍栓; IFN受容体; STAT-phosphoSTAT

1) The relationship of the antitumor effect and suppression and angiogenesis The anti-tumor effect was compared by measuring tumor diameter among 4 treatment regimens, control, 5-FU, IFN-α, 5-FU and IFN-α therapy, in human tumor cells-implanted mice. The anti-tumor effect was best observed in the 5-FU and TFN-a therapy group and this effect was significantly correlated with micro-vessel density. Among angiogenic factors examined, the expression of angiopoietin2 was most significantly correlated with anti-angiogenesis.2) Anti tumor effect through TRAIL/TRAIL receptor and Fas/FasLIFN-α and 5-FU enhanced TRAIL expression in peripheral mononuclear cells, and TRAIL receptor in cultured hepatoma cells. Among peripheral blood cells, NK cells were found to exert the cytotoxic effects on human hepatoma cells. In addition, the involvement of Fas/FasL system in the anti tumor effect was examined and confirmed in this study.

1) 抗肿瘤效果与抑制和血管生成的关系通过测量4种治疗方案（对照、5-FU、IFN-α、5-FU和IFN-α治疗）在人类肿瘤中的肿瘤直径来比较抗肿瘤效果在5-FU和TFN-a治疗组中观察到的抗肿瘤效果最好，并且这种效果与所检查的微血管密度显着相关。血管生成素2与抗血管生成显着相关。2)通过TRAIL/TRAIL受体和Fas/FasLIFN-α和5-FU增强外周单核细胞中TRAIL表达以及培养的肝癌细胞中TRAIL受体的抗肿瘤作用。 ，发现NK细胞对人肝癌细胞发挥细胞毒作用。此外，本研究还检验并证实了Fas/FasL系统参与抗肿瘤作用。

项目成果

Xu X., Nagano H.et al.: "Overexpression of CDC25A phosphatase is ssociated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas."Clinical Cancer Research. 9. 1764-1772 (2003)

Xu X.、Nagano H.等人：“CDC25A 磷酸酶的过度表达与人类肝细胞癌的过度生长活性和不良预后相关。”临床癌症研究。

永野浩昭, 左近賢人, 他: "肝細胞癌に対する新治療法の開発研究"日本臨牀. 60(11). 2237-2244 (2002)

Hiroaki Nagano、Kento Sakon 等：“肝细胞癌新疗法的开发研究”Nippon Rinsho 60(11) 2237-2244 (2002)。

Xu X., Nagano H., et al.: "Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas."Clinical Canser Research. 9. 1764-1772 (2003)

Xu X.、Nagano H. 等人：“CDC25A 磷酸酶的过度表达与人类肝细胞癌的过度生长活性和不良预后相关。”临床 Canser 研究。

Sakon M., Nagano H.et al.: "Combined intraarterial 5-Fluorouracil and Subcutaneous interferon-a therapy advanced hepatocellular carcinoma withtumor thrombi in the major portal branches"Cancer. 94(2). 435-442 (2002)

Sakon M.、Nagano H.等人：“联合动脉内 5-氟尿嘧啶和皮下干扰素-a 治疗晚期肝细胞癌，并在主要门静脉分支中形成肿瘤血栓”癌症。

Shimizu J., Nagano H.et al.: "Noninvasive quantitative measurement of tissue blood flow in hepatocellular carcinoma using xenon-enhanced computed tomography"Dig Dis Sci. 48(8). 1510-1516 (2003)

Shimizu J.、Nagano H.等人：“使用氙气增强计算机断层扫描对肝细胞癌组织血流进行无创定量测量”Dig Dis Sci。